| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pulse Biosciences, Inc$26.29
-0.89 (-3.27%)
D 36Pipeline Score MedTech · Commercial
Market Cap
1.79 B
EPS
-1.10
P/E Ratio
-
Value Trade
6.48 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
401.00 K
R&D Expenses
12.59 M
Operating CF
-14.60 M
Total Assets
81.62 M
Total Liabilities
15.32 M
Equity
66.30 M
D/E Ratio
12,345
-0.99 %
Week
6.46 %
1 Month
5.93 %
3 Month
103.86 %
6 Month
36.55 %
5 Year
526.88 %
All Time
Cash Data
Cash Position
68.32 M
Monthly Burn
4.87 M
Runway
12.3 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
257.62 K
52 Week Range
12.56 - 27.98
% held by Insiders
73.3 %
% held by Institutions
11.48 %
Enterprise Value
1.73 B
Total Shares
68.30 M
Short %
15.72 %
Float Shares
18.17 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D36
Pipeline Score $259M
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 49%
Micro Cap (rank 466 of 911)
Percentile RankPulse Biosciences, Inc faces pipeline headwinds (36/100), with $766M risk-adjusted pipeline value, led by pVAXrcPSAv53l in Prostate Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pVAXrcPSAv53l Monoclonal antibody | Prostate Cancer | Phase 1 | NCT00859729 | 17% | $705M | COMPLETED | 15 | - | - | Nov 1, 2011 | - | Mar 17, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nPulse Cardiac Catheter Ablation System | Atrial Fibrillation (AFib) | — | 2026-03-17 | 100% Procedural Success at 6 Months: 75/75 evaluable patients achieved acute Pulmonary Vein Isolation (PVI) success.; 96% Sustained Success at 12 Months: Long-term follow-up (45/47 patients) confirmed highly durable Pulmonary Vein Isolation (PVI), exceeding traditional expectations in a field where approximately 20-25% recurrence is common.; Industry-Leading Procedural Efficiency: Left Atrial Dwell Time: 21.0 ± 13.3 minutes, Total Procedure Time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy.; Safety Profile: A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint. Read More | Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data Read More | |
nPulse Cardiac Catheter Ablation System | Atrial Fibrillation (AFib) | — | 2026-03-17 | 100% Procedural Success at 6 Months: 75/75 evaluable patients achieved acute Pulmonary Vein Isolation (PVI) success.; 96% Sustained Success at 12 Months: Long-term follow-up (45/47 patients) confirmed highly durable Pulmonary Vein Isolation (PVI), exceeding traditional expectations in a field where approximately 20-25% recurrence is common.; Industry-Leading Procedural Efficiency: Left Atrial Dwell Time: 21.0 ± 13.3 minutes, Total Procedure Time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy.; Safety Profile: A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint. Read More | Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data Read More | |
nPulse Cardiac Catheter Ablation System | Atrial Fibrillation (AFib) | — | 2026-03-17 | 100% Procedural Success at 6 Months: 75/75 evaluable patients achieved acute Pulmonary Vein Isolation (PVI) success.; 96% Sustained Success at 12 Months: Long-term follow-up (45/47 patients) confirmed highly durable Pulmonary Vein Isolation (PVI), exceeding traditional expectations in a field where approximately 20-25% recurrence is common.; Industry-Leading Procedural Efficiency: Left Atrial Dwell Time: 21.0 ± 13.3 minutes, Total Procedure Time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy.; Safety Profile: A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint. Read More | Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLSE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PLSE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PLSEPulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. has announced its intention to redeem outstanding warrants. This move is part of the company's ongoing financial strategy. Further details regarding the implications of this redemption have not been disclosed in the announcement.
Read more →PLSEPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pulse Biosciences is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The event will provide an opportunity for the company to share insights and updates with investors and stakeholders. Further details regarding the presentation are currently not available.
Read more →PLSE▲ +22.1%on this news
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences' co-chairmen have made ATM equity purchases totaling around $13.3 million. This move indicates confidence in the company's future, although specific details regarding the implications of these purchases are not provided.
Read more →PLSEPulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences is scheduled to present at the BofA Securities 2026 Healthcare Conference. The details regarding the presentation content and timing have not been disclosed in the article. This conference is a significant event for healthcare companies to showcase their innovations and strategies.
Read more →PLSEPulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences has reported its business updates and financial results for the first quarter of 2026. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or business developments are not disclosed in the provided text.
Read more →PLSEPulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences showcased promising updated data regarding their nPulse™ Cardiac Catheter System at the Heart Rhythm 2026 event. The outcomes presented indicate significant advancements in cardiac care, emphasizing the system's efficacy. This presentation marks a crucial step in the company's ongoing commitment to improving patient outcomes in cardiology.
Read more →PLSEPulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences will showcase its nPulse™ technology at the Heart Rhythm Society 2026 Annual Meeting. This event is significant for the company as it highlights their innovative approach in the field of cardiac health. Further details about the technology's applications and benefits are anticipated during the meeting.
Read more →PLSE▲ +14.1%on this newsshared move
Pulse Biosciences to Host Analyst Event on April 25, 2026
Pulse Biosciences has announced an upcoming analyst event scheduled for April 25, 2026. Details regarding the event's agenda or topics have not been disclosed in the article. The announcement signifies the company's ongoing engagement with investors and analysts. Further information may be expected as the event date approaches.
Read more →PLSEPulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg's role as Chief Medical Officer. This strategic move aims to enhance the company's focus on the development and commercialization of its nPulse Cardiac Catheter Ablation System. Teplitsky brings extensive experience in medical technology, while Kenigsberg's expanded role will support ongoing clinical studies.
Read more →PLSE▼ -13%on this newsshared move
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Pulse Biosciences has successfully enrolled the first patients in its NANOPULSE-AF IDE pivotal clinical study. This study aims to evaluate the effectiveness of the nPulse™ Cardiac Catheter System in treating atrial fibrillation. The enrollment marks a significant milestone in the development of this innovative treatment approach.
Read more →PLSEPulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The company is known for its nPulse platform, which utilizes Nanosecond Pulsed Field Ablation technology. This innovative approach aims to enhance patient treatment options, particularly in areas like atrial fibrillation and surgical soft tissue ablation.
Read more →PLSEPulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences has announced a strategic alignment to accelerate the development of its nPulse Cardiac Catheter Ablation System following positive clinical data from a 150-patient study. The results demonstrated high procedural success and durability in treating Atrial Fibrillation (AFib). The company is reallocating resources to focus on this promising program, which is set to undergo pivotal studies in the U.S. and Europe.
Read more →PLSEPulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences has announced promising long-term results from its nPulse Vybrance system for the ablation of benign thyroid nodules. The study showed a significant average volume reduction of 74% at 15-22 months post-treatment, with no adverse events or tissue regrowth. Patient satisfaction rates were high, indicating potential for future applications of this technology.
Read more →PLSEPulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. has announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The presentation is scheduled for March 18, 2026, where the company will discuss its proprietary nPulse technology. This technology aims to improve patient care through non-thermal energy applications in medical treatments.
Read more →PLSEPulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
Pulse Biosciences announced that its nPulse technology will be featured at the North American Society for Interventional Thyroidology Meeting. Presentations will include long-term follow-up data from the nPulse Vybrance feasibility study. The company aims to advance the treatment of benign thyroid nodules using its proprietary nanosecond pulsed field ablation technology.
Read more →PLSE▼ -14.6%on this news
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
Pulse Biosciences, Inc. is set to present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026. The presentation will highlight the company's innovative nPulse technology, which utilizes nanosecond pulsed field ablation. This technology aims to improve patient care, particularly in treating atrial fibrillation and surgical soft tissue ablation.
Read more →PLSE▲ +51.6%on this news· ran to +84% by day 3
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences announced promising late-breaking data from its nPulse Cardiac Catheter first-in-human feasibility study, demonstrating a 100% procedural success rate at 6 months. The study involved 150 patients and highlighted the system's strong safety profile and rapid procedure times. The findings were presented at the AF Symposium 2026, indicating a significant advancement in atrial fibrillation treatment.
Read more →PLSE▼ -9.4%on this news· ran to +58% by day 3shared move
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
Pulse Biosciences, Inc. will announce its fourth quarter and full year 2025 financial results on February 19, 2026. A conference call will follow the announcement, allowing investors to engage with company management. The company is focused on advancing its nPulse technology for various medical applications.
Read more →PLSE▲ +7.6%on this news· ran to +72% by day 3shared move
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences announced that its nPulse Cardiac Catheter will be featured at the AF Symposium 2026, including a late-breaking science session and live case transmission. The company will present 6-month and 12-month follow-up data from its Human Feasibility Study in Europe, showcasing the potential of its nanosecond PFA technology for atrial fibrillation treatment. This marks a significant milestone for Pulse Biosciences as they engage with the clinical community.
Read more →PLSEPulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Pulse Biosciences has appointed Maria Sainz to its Board of Directors, effective January 9, 2026. Sainz, with over 30 years of experience in healthcare technology, is expected to provide strategic guidance as the company advances its clinical programs. Her previous leadership roles in various medical device companies highlight her capability to drive growth and commercialization.
Read more →PLSEPulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences, Inc. has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026. The company will showcase its proprietary nPulse technology, which utilizes nanosecond pulsed field ablation to improve patient care. A live webcast of the presentation will be available on their investor website.
Read more →PLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025
Pulse Biosciences has granted equity inducement awards to two new employees under Nasdaq Listing Rule 5635(c)(4). The awards, approved on December 15, 2025, allow the purchase of 3,400 shares at an exercise price of $14.13 each. These options will vest over four years, contingent on the employees' continued employment.
Read more →PLSE▲ +13%on this news
Taxonomy2022_ Pulse Biosciences Reports Third Quarter 202 2 Financial Results  HAYWARD, Calif. [Business Wire] – November 1 0 , 202 2 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric me
Pulse Biosciences Reports Third Quarter 2022 Financial Results HAYWARD, Calif. [Business Wire] November 10, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX System which harnesses and effectively controls the appl
Read more →PLSEPulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation Strategic focus shifting to advance core NPS technology in cardiac and
Pulse Biosciences, Inc. 8-K Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation Strategic focus shifting to advance core NPS technology in cardiac and oncology sectors activate a
Read more →PLSE▲ +6.9%on this news
Taxonomy2022_ Pulse Biosciences Reports Second Quarter 202 2 Financial Results  HAYWARD, Calif. [Business Wire] – August 1 0 , 202 2 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric med
Pulse Biosciences Reports Second Quarter 2022 Financial Results HAYWARD, Calif. [Business Wire] August 10, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology, tod
Read more →PLSETaxonomy2022 Pulse Biosciences, Inc. Announces the Closing of its Rights Offering  HAYWARD, Calif. [Business Wire] – June 9 , 2022 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Companyȁ
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering HAYWARD, Calif. [Business Wire] June 9, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pu
Read more →PLSEPulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering  HAYWARD, Calif. [Business Wire] – June 3 , 2022 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” o
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering HAYWARD, Calif. [Business Wire] June 3, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company commercializing the CellFX System powered b
Read more →PLSEPulse Biosciences, Inc. Announces Changes to its Rights Offering  HAYWARD, Calif. [Business Wire] – May 1 9 , 2022 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pu
Pulse Biosciences, Inc. Announces Changes to its Rights Offering HAYWARD, Calif. [Business Wire] May 19, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company commercializing the CellFX System Powered by Nano-Pulse
Read more →PLSE▼ -17.2%on this news· ran to -36% by day 1
P ulse Biosciences Reports First Quarter 2022 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports First Quarter 2022 Financial Results HAYWARD, Calif. [Business Wire] May 11, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology, today a
Read more →PLSETHE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE "PROSPECTUS"), AND ARE IN
THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE "PROSPECTUS"), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS AR
Read more →PLSE▼ -6.7%on this news
Pulse Biosciences, Inc. Announces Rights Offering HAYWARD, Calif. [Business Wire]
Pulse Biosciences, Inc. Announces Rights Offering HAYWARD, Calif. [Business Wire] - April 14, 2022 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company, today announced that the Company's Board of Directors has approv
Read more →PLSEP ulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results HAYWARD, Calif. [Business Wire] March 31, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) tech
Read more →PLSE▼ -5.8%on this news
Pulse Biosciences, Inc. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against in the United States District Court for the Northern District of California against Pulse Biosciences, Inc.
NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors who purchased Pulse Bio
Read more →PLSEPulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer HAYWARD, Calif. [Business Wire] – February 9 , 2022 . Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine co
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer HAYWARD, Calif. [Business Wire] February 9, 2022. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulat
Read more →PLSE▼ -34.4%on this news
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission HAYWARD, Calif. [Business Wire] February 8, 2022. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technolo
Read more →PLSEPulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results HAYWARD, Calif. [Business Wire] January 11, 2022. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by
Read more →PLSEPulse Biosciences Reports Third Quarter 2021 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports Third Quarter 2021 Financial Results HAYWARD, Calif. [Business Wire] November 15, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology, to
Read more →PLSExFEFF;  Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors  HAYWARD, Calif. [Business Wire]– Oct. 5 , 2021 . Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine c
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors HAYWARD, Calif. [Business Wire] Oct. 5, 2021. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology,
Read more →PLSExFEFF;  Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer  HAYWARD, Calif. [Business Wire]–
Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer HAYWARD, Calif. [Business Wire] August 19, 2021. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimula
Read more →PLSEPulse Biosciences Reports Second Quarter 2021 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports Second Quarter 2021 Financial Results HAYWARD, Calif. [Business Wire] August 9, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology, toda
Read more →PLSEPulse Biosciences Announces $50 Million Private Placement HAYWARD, Calif. [Business Wire]–
Pulse Biosciences Announces $50 Million Private Placement HAYWARD, Calif. [Business Wire] July 1, 2021. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS ) technology, today annou
Read more →PLSEPulse Biosciences Announces Health Canada Approval for CellFX ® System  - Company to Expand Global Controlled Launch Program with Clinical Aesthetic Experts in Canada  HAYWARD, Calif.--( BUSINESS WIR
Pulse Biosciences Announces Health Canada Approval for CellFX System - Company to Expand Global Controlled Launch Program with Clinical Aesthetic Experts in Canada HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) ( Pulse Biosciences or the Company ), a n
Read more →PLSEPulse Biosciences Reports First Quarter 2021 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports First Quarter 2021 Financial Results HAYWARD, Calif. [Business Wire] May 10, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation (NPS ) technology, today announced financial results fo
Read more →PLSEPulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results HAYWARD, Calif. [Business Wire] February 22, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation (NPS ) technology, today announced
Read more →PLSEPulse Biosciences, Inc. Announces At-The-Market Equity Offering Program
Pulse Biosciences, Inc. Announces At-The-Market Equity Offering Program HAYWARD, Calif., February 4, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS ) technology, today
Read more →PLSEPulse Biosciences Announces FDA Clearance for the CellFX® System  - CellFX System delivers Nano-Pulse Stimulation Technology in dermatologic procedures - U.S. controlled launch to commence  HAYWARD,
Pulse Biosciences Announces FDA Clearance for the CellFX System - CellFX System delivers Nano-Pulse Stimulation Technology in dermatologic procedures - U.S. controlled launch to commence HAYWARD, Calif. [Business Wire] February 3, 2021. Pulse Biosciences, Inc. (Nasdaq: PLSE),
Read more →PLSEPulse Biosciences Announces CE Mark Approval for CellFX® System  - CellFX System Delivers Nano-Pulse Stimulation Technology to Clear Hard-to-Treat Benign Skin Lesions - First CellFX System Shipment Scheduled
Pulse Biosciences Announces CE Mark Approval for CellFX System - CellFX System Delivers Nano-Pulse Stimulation Technology to Clear Hard-to-Treat Benign Skin Lesions - First CellFX System Shipment Scheduled to Commence Controlled Launch Program with Clinical Aesthetic Experts in
Read more →PLSEPulse Biosciences, Inc. Announces Redemption of Warrants 
Pulse Biosciences, Inc. Announces Redemption of Warrants HAYWARD, Calif., January 5, 2021 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS ) technology, announced today that
Read more →PLSEPulse Biosciences Reports Third Quarter 2020 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports Third Quarter 2020 Financial Results HAYWARD, Calif. [Business Wire] November 9, 2020 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation (NPS ) technology, today announced financial results
Read more →PLSEP ulse Biosciences Reports Second Quarter 2020 Financial Results  HAYWARD , Calif. [Business Wire] – August 10 , 2020 . Pulse Biosciences, Inc. (Nasdaq: PLSE ), a novel bioelectric medicine company progres
Pulse Biosciences Reports Second Quarter 2020 Financial Results HAYWARD, Calif. [Business Wire] August 10, 2020. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS ) technology, today announced financial results f
Read more →PLSEPulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors  HAYWARD, Calif., August 6 , 2020 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Bioscie
Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors HAYWARD, Calif., August 6, 2020 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences ), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS ) technology, a
Read more →PLSEPulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering HAYWARD, Calif., June 16, 2020 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, announced today the closing of its oversubscribed rights
Read more →PLSEPULSE BIOSCIENCES
PULSE BIOSCIENCES, INC. ANNOUNCES PRELIMINARY RESULTS FOR ITS OVERSUBCRIBED RIGHTS OFFERING HAYWARD, Calif., June 8, 2020 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, today announced preliminary results o
Read more →PLSExFEFF; Pulse Biosciences Reports First Quarter 2020 Financial Results  HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Reports First Quarter 2020 Financial Results HAYWARD, Calif. [Business Wire] May 11, 2020. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the first quarter ended March 31, 2020. Amid the diff
Read more →PLSEPulse Biosciences, Inc. Announces Updated Structure, Dates and Pricing Terms for Rights Offering
Pulse Biosciences, Inc. Announces Updated Structure, Dates and Pricing Terms for Rights Offering HAYWARD, Calif., May 1, 2020 -- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, today announced that it has updat
Read more →PLSEPulse Biosciences files Registration Statement for Rights Offering
Pulse Biosciences files Registration Statement for Rights Offering HAYWARD, Calif. - April 6, 2020 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company", or "Pulse Biosciences") today announced that it filed a registration statement on Form S-3 with the Securities and Exchange
Read more →PLSExFEFF; Pulse Biosciences Report Fourth Quarter and Full Year 2019 Financial Results   HAYWARD, Calif. [Business Wire] –
Pulse Biosciences Report Fourth Quarter and Full Year 2019 Financial Results HAYWARD, Calif. [Business Wire] March 16, 2020. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the fourth quarter and full year ended
Read more →PLSEPULSE BIOSCIENCES PROVIDES UPDATE ON FDA 510(k) SUBMISSION FOR THE CELLFX SYSTEM IN DERMATOLOGY Schedules Business Update Call on
PULSE BIOSCIENCES PROVIDES UPDATE ON FDA 510(k) SUBMISSION FOR THE CELLFX SYSTEM IN DERMATOLOGY Schedules Business Update Call on February 18, 2020 at 2:00pm PT HAYWARD, Calif. [Business Wire] February 13, 2020. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medici
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT   HAYWARD, Calif. - (BUSINESS WIRE) – – Pulse Biosciences, Inc. (N
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company ), a novel bioelectric medicine company bringing to market its proprietary CellFX Sy
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT   HAYWARD, Calif. - (BUSINESS WIRE) – August 8 , 201 9 – Pulse Bio
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) August 8, 2019 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company ), a novel bioelectric medicine company bringing to market its propri
Read more →PLSExFEFF;  C/ O BROADRIDG E CORPOR A T E ISSUE R SOLUTION S, INC. P.O. BOX 1342 BRENTWOOD, NY 11717  Date SEQ# Name1 Name2 Name3 Name4 Address1 Address2 Address3 Address4 City, State ZIP Country  Dea
C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. We are pleased to announce that we have appointed Broadridge Corporate Issuer Solutions, Inc. ( Broadridge ) as the transfer agent and registrar for the shares of our common stock. In this capacity, Broadridge will manage all stock
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT  HAYWARD, Calif. - (BUSINESS WIRE) – April 30 , 2019 – Pulse Biosciences,
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) April 30, 2019 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company ), a novel bioelectric medicine company bringing to market its propri
Read more →PLSExFEFF;  PULSE BIOSCIENCES APPOINTS MITCHELL LEVINSON TO BOARD OF DIRECTORS HAYWARD, Calif.--(BUSINESS WIRE)--Mar. 19 , 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE) (“Pulse Biosciences” or the ȁ
PULSE BIOSCIENCES APPOINTS MITCHELL LEVINSON TO BOARD OF DIRECTORS HAYWARD, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Pulse Biosciences, Inc.(NASDAQ:PLSE) ( Pulse Biosciences or the Company ), a novel medical therapy company bringing to market its proprietary CellFX System, today
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  First patient treated in the CellFX ™ back acne feasibility study  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT  HAYWA
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL First patient treated in the CellFX back acne feasibility study Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) February 7, 2019 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel medica
Read more →PLSExFEFF; PULSE BIOSCIENCES ANNOUNCES TWO APPOINTMENTS FOCUSED ON CellFX TM COMMERCIALIZATION: PROMOTION OF EDWARD EBBERS AND ADDITION OF ROBERT TYSON  - Ebbers named Executive Vice President and General Manager, De
PULSE BIOSCIENCES ANNOUNCES TWO APPOINTMENTS FOCUSED ON CellFXTM COMMERCIALIZATION: PROMOTION OF EDWARD EBBERS AND ADDITION OF ROBERT TYSON HAYWARD, Calif. - (BUSINESS WIRE) January 17, 2019 Pulse Biosciences, Inc. (NASDAQ:PLSE), a medical technology company bringing to market
Read more →PLSExFEFF; PULSE BIOSCIENCES, Inc. Announces CLOSING OF its $45 million RIGHTS OFFERING  HAYWARD, Calif. - (BUSINESS WIRE) – Dec ember 14 , 2018 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse B
PULSE BIOSCIENCES, Inc. Announces CLOSING OF its $45 million RIGHTS OFFERING HAYWARD, Calif. - (BUSINESS WIRE) December 14, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE) ( Pulse Biosciences or the Company ), a novel medical therapy company bringing to market its proprietary CellFX
Read more →PLSExFEFF; PULSE BIOSCIENCES, Inc. Announces over Subscription , Pricing AND PRELIMINARY RESULTS FOR its $45 million RIGHTS OFFERING  HAYWARD, Calif. - (BUSINESS WIRE) – Dec ember 7 , 2018 – Pulse Biosc
PULSE BIOSCIENCES, Inc. Announces overSubscription, Pricing AND PRELIMINARY RESULTS FOR its $45 million RIGHTS OFFERING HAYWARD, Calif. - (BUSINESS WIRE) December 7, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE) ( Pulse Biosciences or the Company ), a novel medical therapy company
Read more →PLSEFORWARD-LOOKING STATEMENTS This investor overview provided by Pulse Biosciences, Inc., contains estimates and forward-looking statements including, among others, statements regarding Pulse Biosciences' future business pl
FORWARD-LOOKING STATEMENTS This investor overview provided by Pulse Biosciences, Inc., contains estimates and forward-looking statements including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, clinical trials, r
Read more →PLSEPULSE BIOSCIENCES, INC. ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING HAYWARD, Calif. - (BUSINESS WIRE)
PULSE BIOSCIENCES, INC. ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING HAYWARD, Calif. - (BUSINESS WIRE) - November 19, 2018 - Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse Biosciences" or the "Company"), a novel medical therapy company bringing to market its proprietary CellFX Nan
Read more →PLSExFEFF; PULSE BIOSCIENCES, Inc. Announces Record Date, Subscription Pricing, A ND Expiration Date for Rights Offering and Effectiveness of Its Registration Statement  HAYWARD, Calif. - (BUSINESS WIRE) –
PULSE BIOSCIENCES, Inc. Announces Record Date, Subscription Pricing, AND Expiration Date for Rights Offering and Effectiveness of Its Registration Statement HAYWARD, Calif. - (BUSINESS WIRE) November 7, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE) ( Pulse Biosciences or the Com
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT   HAYWARD, Calif. - (BUSINESS WIRE) – October 30 , 2018 – Pulse Bi
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) October 30, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse S
Read more →PLSExFEFF; Pulse Biosciences files Registration Statement for Rights Offering  HAYWARD, Calif. – October 2 5 , 2018 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”, or “Puls
Pulse Biosciences files Registration Statement for Rights Offering HAYWARD, Calif. October 25, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company , or Pulse Biosciences ) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Co
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT   HAYWARD, Calif. - (BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. - (BUSINESS WIRE) July 31, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical stage electroceutical company developing a proprietary therapeutic tiss
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  C onference call today at 1:30 p.m. PDT / 4:30 p.m. EDT  HAYWARD, Calif.—(BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. (BUSINESS WIRE) March 16, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment
Read more →PLSEPULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL  Investor conference call today at 1:30 p.m. PST / 4:30 p.m. ES T  HAYWARD, Calif.—(BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Investor conference call today at 1:30 p.m. PST / 4:30 p.m. EST HAYWARD, Calif. (BUSINESS WIRE) November 7, 2017 Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic tissue
Read more →PLSEPulse Biosciences Announces Transition of Board of Directors , E xtend s A ppreciation to Retiring Members and Welcomes New Board Members Bob Duggan A ssumes Chairman ship, Ken Clark, Wilson Sonsini Goodrich & Rosati, Dr
Pulse Biosciences Announces Transition of Board of Directors, Extends Appreciation to Retiring Members and Welcomes New Board Members Bob Duggan Assumes Chairmanship, Ken Clark, Wilson Sonsini Goodrich & Rosati, Dr. Thomas Fogarty, Fogarty Institute of Innovation, and Manmeet S
Read more →PLSEP ulse Biosciences Announces $30 Million Private Placement HAYWARD, Calif.--(BUSINESS WIRE)--Sept ember 25 , 2017-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeuti
Pulse Biosciences Announces $30 Million Private Placement HAYWARD, Calif.--(BUSINESS WIRE)--September 25, 2017-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) p
Read more →PLSExFEFF; PULSE BIOSCIENCES ANNOUNCES WITHDRAWAL AND PLANNED RESUBMISSION OF 510(k) APPLICATION FOR THE PULSETX TM SYSTEM HAYWARD, Calif.— (BUSINESS WIRE) – September 11 , 2017 – Pulse Biosciences, Inc.
PULSE BIOSCIENCES ANNOUNCES WITHDRAWAL AND PLANNED RESUBMISSION OF 510(k) APPLICATION FOR THE PULSETXTM SYSTEM HAYWARD, Calif. (BUSINESS WIRE) September 11, 2017 Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue trea
Read more →PLSEPULSE BIOSCIENCES QUARTER L Y INVESTOR AND ANALYST CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD , Calif.—(BUSINESS WIRE) – July 27 , 2017 – Pulse Bioscience
PULSE BIOSCIENCES QUARTERLY INVESTOR AND ANALYST CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. (BUSINESS WIRE) July 27, 2017 Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeut
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTER L Y INVESTOR CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. —(BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. (BUSINESS WIRE) May 4, 2017 Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue t
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERY INVESTOR CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. —(BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERY INVESTOR CONFERENCE CALL Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. (BUSINESS WIRE) March 14, 2017 Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue
Read more →PLSE02-10 Pulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquire d a Combined Interest of 17.1% of the Company - Company A ppoints Dr. Maky Zang aneh to Company B
Pulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquired a Combined Interest of 17.1% of the Company - Company Appoints Dr. Maky Zanganeh to Company Board of Directors - BURLINGAME, Calif. February 10, 2017 Pulse Bios
Read more →PLSExFEFF; PULSE BIOSCIENCES QUARTERY NANO-PULSE STIMULATION (NPS) UPDATE Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. —(BUSINESS WIRE) –
PULSE BIOSCIENCES QUARTERY NANO-PULSE STIMULATION (NPS) UPDATE Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. (BUSINESS WIRE) Nov. 14, 2016 Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeu
Read more →PLSExFEFF; Pulse Biosciences Provides Overview of Corporate Strategy and Updates on Clinical Development for Novel PulseTx Platform Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. (BUSINESS
Pulse Biosciences Provides Overview of Corporate Strategy and Updates on Clinical Development for Novel PulseTx Platform Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif. (BUSINESS WIRE) Sep. 7, 2016 Pulse Biosciences, Inc., (NASDAQ: PLSE), a me
Read more →PLSEPulse Biosciences Announces Closing of Initial Public Offering Over-allotment
BURLINGAME, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its underwriters’ over-allotment for 749,846 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of approximately $3.0 mill
Read more →PLSEPulse Biosciences Announces Closing of Initial Public Offering
BURLINGAME, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its initial public offering of 5,000,000 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of $20 million before customary
Read more →PLSEPulse Biosciences Announces Pricing of Initial Public Offering
BURLINGAME, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $4.00 per share. All of the 5,000,000 shares are being offered by Pulse Bios
Read more →Competitive Position
How PLSE ranks across every disease it competes inCompetitive Position is a premium feature
See how PLSE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial